SynAct Pharma AB
SYNACT
Rank in Stocks
#20300
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS,... SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Share Price
$1.56
Last synced: 2026-11-09
Market Cap
$87.30M
Change (1 day)
0.92%
Change (1 year)
-30.94%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade SynAct Pharma AB (SYNACT)
Category
Healthcare
EPS for SynAct Pharma AB (SYNACT)
EPS as of September 2026 TTM: $-0.19
According to SynAct Pharma AB's latest financial reports, its current EPS (TTM) is $-0.19. At the end of 2025 the company had an EPS of $-0.24, a decrease compared to its 2024 EPS of $-0.19.
EPS history for SynAct Pharma AB from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.19 | -21.38% |
| 2025 | $-0.24 | 24.71% |
| 2024 | $-0.19 | -71.35% |
| 2023 | $-0.66 | 90.67% |
| 2022 | $-0.35 | 17.02% |
| 2021 | $-0.30 | 98.25% |
| 2020 | $-0.15 | -14.24% |
| 2019 | $-0.17 | -8.83% |
| 2018 | $-0.19 | 25.44% |
| 2017 | $-0.15 | 6.01% |
| 2016 | $-0.14 | 762.05% |
| 2015 | $-0.02 | -0.60% |
| 2014 | $-0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -8,398.89% |
US
|
|
| $-7.07 | 3,646.69% |
US
|
|
| $-5.29 | 2,703.39% |
AU
|
|
| $12.88 | -6,925.70% |
BE
|
|
| $21.56 | -11,525.54% |
NL
|
Questions about SynAct Pharma AB's earnings per share (EPS)
What is SynAct Pharma AB's earnings per share (EPS)?
SynAct Pharma AB's earnings per share (EPS) over the last twelve months is $-0.19, as of Sep 2026.
What was SynAct Pharma AB's earnings per share (EPS) in 2025?
In 2025, SynAct Pharma AB's earnings per share (EPS) was $-0.24, compared with $-0.19 in 2024.
How has SynAct Pharma AB's earnings per share (EPS) changed since 2020?
From 2020 to 2025, SynAct Pharma AB's earnings per share (EPS) was highest in 2020 ($-0.15) and lowest in 2023 ($-0.66).
How does SynAct Pharma AB's earnings per share (EPS) compare with similar companies?
SynAct Pharma AB's earnings per share (EPS) ($-0.19) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.